Ipidakrin (Tablets, Solution) Instructions for Use

ATC Code

N06DA05 (Ipidacrine)

Active Substance

Ipidacrine (Rec.INN registered by WHO)

Clinical-Pharmacological Group

Cholinesterase inhibitor

Pharmacotherapeutic Group

Psychoanaleptics; agents for the treatment of dementia; anticholinesterase agents

Pharmacological Action

Cholinesterase inhibitor. Prevents the enzymatic hydrolysis of acetylcholine and prolongs its action. Blocks potassium channels of membranes and promotes their depolarization.

Stimulates synaptic transmission in neuromuscular endings, conduction of excitation in nerve fibers, enhances the effect on smooth muscles of acetylcholine and other mediators (including epinephrine, serotonin, histamine, oxytocin), restores neuromuscular transmission and conduction of excitation in the peripheral nervous system (due to disorders of various origins: trauma, inflammation, action of local anesthetics, antibiotics, toxins, potassium chloride).

Increases the tone and contractility of the smooth muscles of internal organs, including the gastrointestinal tract and bronchi (up to bronchospasm), reduces heart rate, enhances the secretion of salivary glands, the contractile activity of the myometrium, and the tone of skeletal muscles.

It has a stimulating effect on the central nervous system in combination with individual manifestations of a sedative effect; promotes improvement of learning and memory.

Indications

Diseases of the peripheral nervous system (neuritis, polyneuritis, polyneuropathy, polyradiculopathy), bulbar paralysis and paresis.

In the recovery period for organic lesions of the central nervous system, accompanied by motor and/or cognitive impairments.

Myasthenia gravis, myasthenic syndrome.

Demyelinating diseases (as part of complex therapy).

Alzheimer’s disease, senile dementia of the Alzheimer’s type.

Functional disorders of the central nervous system (memory loss, decreased ability to concentrate, motivation, initiative, disorientation, emotional lability, etc.) in encephalopathy (of traumatic, vascular and other origins), cerebrovascular accident, traumatic brain injury, cerebral dysfunction with learning difficulties in children.

Weakness of labor activity.

Intestinal atony.

Intoxication with anticholinergic agents.

ICD codes

Dosage Regimen

Administer orally, subcutaneously, or intramuscularly.

For subcutaneous or intramuscular injection, use a single dose of 5 mg to 30 mg.

The maximum daily dose is 200 mg; do not exceed this limit.

For peripheral nervous system diseases (neuritis, polyneuropathy), use 10-40 mg orally up to four times daily.

For myasthenia gravis and myasthenic syndrome, administer 15-30 mg orally three to five times per day.

For Alzheimer’s disease and senile dementia, initiate therapy with 10 mg orally once or twice daily.

Titrate the dose gradually based on tolerance and efficacy; the typical maintenance dose is 20 mg taken two to three times daily.

For functional CNS disorders and encephalopathy, use 10-20 mg orally two to three times per day.

In cases of intestinal atony, administer 10-20 mg subcutaneously or intramuscularly.

For weakness of labor activity, use 10-30 mg intramuscularly.

The duration of treatment is determined by the underlying condition and clinical response; courses typically last several weeks to months.

Adjust the frequency of administration and total daily dose according to the patient’s age and clinical status.

Monitor for signs of cholinergic excess, particularly when initiating therapy or increasing the dose.

Adverse Reactions

From the digestive system anorexia, hypersalivation, nausea, vomiting, increased peristalsis, diarrhea, jaundice.

From the central nervous system dizziness (after repeated application), ataxia.

Allergic reactions skin rash, itching.

Other manifestations of m-cholinomimetic action – bronchospasm, bradycardia.

Contraindications

Epilepsy, extrapyramidal disorders with hyperkinesis, angina pectoris, severe bradycardia, bronchial asthma, vestibular disorders, gastric ulcer and duodenal ulcer in the acute phase; mechanical obstruction of the intestine or urinary tract; pregnancy, lactation period, children and adolescents under 18 years of age; hypersensitivity to ipidacrine.

Use in Pregnancy and Lactation

Contraindicated for use during pregnancy and breastfeeding.

Pediatric Use

Contraindicated for use in children and adolescents under 18 years of age.

Special Precautions

Use with caution in gastric ulcer, thyrotoxicosis, diseases of the cardiovascular system. It is necessary to take into account the ability of ipidacrine to increase uterine tone.

Alcohol consumption should be avoided during treatment, as ethanol enhances the side effects of ipidacrine.

Effect on the ability to drive vehicles and mechanisms

Should not be used in patients whose activities are associated with driving vehicles and work requiring high concentration of attention and speed of psychomotor reactions.

Drug Interactions

With simultaneous use, Ipidacrine enhances the sedative effect of drugs that have a depressant effect on the central nervous system, ethanol, the effect of other cholinesterase inhibitors and m-cholinomimetics.

In patients with myasthenia gravis, when using ipidacrine against the background of other cholinergic agents, the risk of developing a cholinergic crisis increases.

With simultaneous use with beta-blockers, bradycardia increases.

Ipidacrine weakens the effect of local anesthetics, antibiotics, potassium chloride.

Atropine and methoctinium iodide reduce the severity of overdose symptoms.

Storage Conditions

Store at 2°C (36°F) to 25°C (77°F). Keep in original packaging, protected from light. Keep out of reach of children.

Dispensing Status

Rx Only

Important Safety Information

This information is for educational purposes only and does not replace professional medical advice. Always consult your doctor before use. Dosage and side effects may vary. Use only as prescribed.